Vanda Pharmaceuticals Inc. (VNDA) News
Filter VNDA News Items
VNDA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VNDA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VNDA News From Around the Web
Below are the latest news stories about VANDA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VNDA as an investment opportunity.
Vanda asserts FDA review of tradipitant was flawedMore on Vanda Pharmaceuticals |
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA ReviewVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. |
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move. |
KOD Stock Rallies 271% in 6 Months on Eye Disease Program UpdatesKodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases. |
3 Under-$10 Drug Stocks Wall Street Analysts Recommend BuyingWe present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025. |
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia VeraVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the treatment of polycythemia vera (PV), a form of a rare hematologic malignancy that is estimated to affect 1 in 2000 Americans.1 |
Exploring Three High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts. |
US Penny Stocks To Watch In December 2024As the U.S. markets navigate a period of uncertainty with the Dow Jones Industrial Average experiencing its longest slump since 1978, investors are keenly watching for the Federal Reserve's upcoming interest rate decision. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention due to their potential for growth at lower price points. While the term "penny stocks" may seem outdated, these investments can still offer unique opportunities... |
New Strong Buy Stocks for November 14thVNDA, TSQ, SPPJY, VMEO and TBI have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2024. |
Vanda Pharmaceuticals Announces Participation at November 2024 Investor ConferencesVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2024: |